Discrepancy in stathmin status was noted in a quarter of paired samples, paralleling findings in e.g. breast cancer where discrepancies between primary and metastatic lesions are shown in 14–55% and 0–40% for hormone receptors and HER2 respectively [45]–[47]. This evidence concerns the gene ERBB2 and breast carcinoma.